MRS. FAY Q NG, RPH
Pharmacy at 23 St, New York, NY
License number
New York 032238
Category
Pharmacy
Type
Pharmacist Clinician (PhC)/ Clinical Pharmacy Specialist
Address
Address
2
423 E 23Rd St, New York, NY 10010
7326 186Th St, Flushing, NY 11366
7326 186Th St, Flushing, NY 11366
Phone
(211) 686-7500
(212) 686-7500
(212) 686-7500
Professional information
Fay Sue Ng, New York NY - Lawyer
Address:
New York City Law Department
100 189Th St RM 6, New York 10007
(212) 356-0843
100 189Th St RM 6, New York 10007
(212) 356-0843
Licenses:
New York - Currently registered 1983
Compounds, Compositions And Methods For Reducing Toxicity And Treating Or Preventing Diseases
US Patent:
2011031, Dec 22, 2011
Filed:
Aug 27, 2009
Appl. No.:
13/061508
Inventors:
Samuel J. Danishefsky - Englewood NJ, US
Ting-Chao Chou - Paramus NJ, US
Xiaoguang Lei - Chao Yang, CN
Heedong Yun - Tenafly NJ, US
Fay Ng - New York NY, US
John Hartung - New York NY, US
Dalibor Sames - New York NY, US
Ting-Chao Chou - Paramus NJ, US
Xiaoguang Lei - Chao Yang, CN
Heedong Yun - Tenafly NJ, US
Fay Ng - New York NY, US
John Hartung - New York NY, US
Dalibor Sames - New York NY, US
Assignee:
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - New York NY
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK - New York NY
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK - New York NY
International Classification:
A61K 31/7048, C07D 317/26, C07D 317/24, C07D 403/04, C07C 43/315, C07C 33/04, C07D 405/06, C07C 33/30, A61K 31/357, A61K 31/4192, A61K 31/075, A61K 31/047, A61P 35/00, A61P 35/02, A61P 25/28, A61P 25/16, A61P 25/18, A61P 25/08, A61P 29/00, A61P 3/00, A61P 39/02, A61K 31/165, A61K 31/661, A61K 31/427, A61K 31/337, A61K 31/343, A61K 31/196, A61K 31/675, C12N 5/071, C07D 317/20
US Classification:
514 27, 549453, 549454, 548255, 568592, 568855, 568873, 514467, 514359, 514718, 514738, 514730, 514629, 514130, 514365, 514449, 514462, 514567, 514110, 435375
Abstract:
The present invention provides compounds of Formula (I), compositions comprising an effective amount of a compound of Formula (I), optionally with chemotherapeutic drugs such as a tubulin-binding drug, and methods of their use for reducing the toxicity of cytotoxic agents, treating or preventing cancer or a neuropathic disorder, inducing a chemoprotective phase II enzyme, DNA, or protein synthesis, enhancing the immune system, treating inflammation, improving and enhancing general health or well-being, and methods for making compounds of Formula (I).
Heteroaryl Derivatives As Superior Ligands For Nociceptin Receptor Orl-1
US Patent:
2003011, Jun 26, 2003
Filed:
Nov 6, 2002
Appl. No.:
10/288976
Inventors:
Deen Tulshian - Lebanon NJ, US
Ginny Ho - Murray Hill NJ, US
Fay Ng - New York NY, US
Ginny Ho - Murray Hill NJ, US
Fay Ng - New York NY, US
Assignee:
Schering Corporation
International Classification:
A61K031/506, A61K031/46, A61K031/522
US Classification:
514/252180, 514/256000, 514/304000, 514/263320, 544/295000, 544/333000, 546/125000
Abstract:
Novel compounds of the formula
wherein R is optionally substituted heteroaryl or
Ris H or C—Calkyl; and Rand Rare —CH, —OCHor halo; or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions therefore, and the use of said compounds in the treatment of pain, anxiety, cough, asthma, depression and alcohol abuse are disclosed.